David Bharucha - 02 Feb 2026 Form 4 Insider Report for Milestone Pharmaceuticals Inc. (MIST)

Role
Chief Medical Officer
Signature
/s/ Joseph Oliveto, Attorney-in-Fact
Issuer symbol
MIST
Transactions as of
02 Feb 2026
Net transactions value
$0
Form type
4
Filing time
04 Feb 2026, 17:50:06 UTC
Previous filing
28 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Bharucha David Chief Medical Officer C/O MILESTONE PHARMACEUTICALS INC., 1111 DR. FREDERIK-PHILIPS BLVD, STE 420, MONTREAL, QUEBEC, CANADA /s/ Joseph Oliveto, Attorney-in-Fact 04 Feb 2026 0001910985
This filing has been restated, see here for the amended filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIST Employee Stock Option (right to buy) Award $0 +204,000 $0.000000 204,000 02 Feb 2026 Common Shares 204,000 $1.97 Direct F1
transaction MIST Restricted Stock Unit Award $0 +136,000 $0.000000 136,000 02 Feb 2026 Common Shares 136,000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.
F2 Each restricted stock unit represents a contingent right to receive one common share.
F3 One-fourth (1/4th) of the shares subject to the restricted stock unit award vest on each of February 2, 2027, February 2, 2028, February 2, 2029 and February 2, 2030, subject to the Reporting Person continuing to provide service through each such date.